Fairvalue-Calculator Fairvalue-Calculator
EN DE

EQL Pharma AB (EQL) Fair Value & Analysis

Healthcare · SE · Market cap 726M SEK

Pricekr 25.15
Fair Valuekr 8.49
Upside-66.2%
Quality97/100
Evidence: Medium Range kr 6.37 – kr 13.26

Fair value as of: Jun 24, 2026

Analysis

EQL Pharma AB (EQL) currently trades at kr 25.15, while our model-based Fair Value estimate is kr 8.49 — implying the stock looks roughly 66.2% overvalued today. We read business quality at 97/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers injection products for inpatient care and formulations for outpatient care. EQL Pharma AB (publ) was incorporated in 2006 and is based in Lund, Sweden.

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +885% Jiangsu Hengrui Pharmaceuticals Co (600276) -44% Sun Pharmaceutical Industries Limited (SUNPHARMA) -49% Zoetis Inc (Z1TS34) -75% Hansoh Pharmaceutical Group (3692) -18% Divi's Laboratories Limited (DIVISLAB) -78%

Frequently asked questions

Is EQL Pharma AB (EQL) undervalued?
As of Jun 24, 2026, our model estimates a fair value of kr 8.49 versus a price of kr 25.15 — about −66% (overvalued). Model-based estimate, not financial advice.
What is the fair value of EQL?
Our 21-model fair value for EQL Pharma AB is kr 8.49 (as of Jun 24, 2026), built from audited fundamentals. The current price is kr 25.15.
What is the quality score of EQL?
EQL Pharma AB has a Quality Score of 97/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.